Kelly Close, a noted diabetes advocate and author, used to be last in line to embrace new diabetes technology. Her conversion from diabetes tech skeptic to believer was quick, especially as she immediately began to feel better on pump therapy. MORE

There is a quiet hacking revolution taking place in the Type 1 diabetes community. While this kind of customized surveillance can be done with current diabetes technology, it has yet to be approved by the FDA. At that time, I knew nothing about diabetes. MORE

There is a quiet hacking revolution taking place in the Type 1 diabetes community. While this kind of customized surveillance can be done with current diabetes technology, it has yet to be approved by the FDA. At that time, I knew nothing about diabetes. MORE

Insulin Nation strives to keep you up to date on the latest news on diabetes gear. Telcare has unveiled a prototype of something it’s billing as a “Total Diabetes Management” solution, but it’s a bit unclear what it is. Next Up, a Diabetes Breath Mint? MORE

If the past year is any indication, diabetes tech geeks might have to work hard in 2017 to keep up with the latest models of pumps and CGMs on the marketplace. As Diabetes Mine reported at the time of the G5 approval, the swiftness of FDA approval caught even Dexcom execs off-guard. MORE

Earlier, we reported on how the Trump administration’s executive order on immigration barred Dr. Samira Asgari from joining a research lab that does diabetes research. So far, no diabetes tech or biopharma company has joined the suit. MORE

I was diagnosed with Type 1 diabetes on September 26, 2015 at 28 years old. My father had been diagnosed with Type 2 diabetes in July of 2015, so there was a history of diabetes in my immediate family. MORE

While you might be going through the same day-in, day-out process to keep blood sugar levels in check, there’s a diabetes technology race afoot. We’ve barely begun 2015, but early returns suggest it’s going to be a banner year for diabetes technology. MORE

The iLet trial can serve as a reminder to the diabetes tech community that while the 670G may be an important introduction to the era of artificial pancreas technology, it will not be the final word. This trial involved 124 people with Type 1 diabetes, ages 14 to 75. MORE

We’ve gotten used to crowdsourcing to fund everything from documentaries to startup clothing lines, but what about advances in diabetes care? Two new fundraising campaigns are crowdsourcing to raise money to foster innovative ways to treat Type 1 diabetes. MORE